Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

Leukemia

Volumn 23, Issue 11, 2009, Pages 2181-2183

  Gutman, D ^a   Morales, A A ^a   Boise, L H ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; EPOXOMICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLYCOPROTEIN P; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SYNDECAN 1;

ARTICLE; CLINICAL TRIAL; HUMAN; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL;

BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHENOTYPE; PROTEASE INHIBITORS; PYRAZINES;

EID: 70450285396     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.123     Document Type: Article

References (8)

1. Kyle RA, Vincent Rajkumar S. Treatment of multiple myeloma: An emphasis on new developments. Ann Med 2006; 38: 111-115.
2. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164-179.
3. Almond JB, Cohen GM. The proteasome: A novel target for cancer chemotherapy. Leukemia 2002; 16: 433-443.
4. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
5. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
6. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21: 4239-4247.
7. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-3290.
8. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006; 106: 830-838.